AlloVir (ALVR) Stock Forecast, Price Target & Predictions
ALVR Stock Forecast
AlloVir stock forecast is as follows: a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
ALVR Analyst Ratings
According to 3 Wall Street analysts, AlloVir's rating consensus is 'Buy'. The analyst rating breakdown for ALVR stock is 1 'Strong Buy' (33.33%), 2 'Buy' (66.67%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Dec 26, 2023 | Raymond James | Strong Buy | Strong Buy | Hold |
| Dec 26, 2023 | Wedbush | Buy | Buy | Hold |
| May 18, 2022 | Piper Sandler | Overweight | Overweight | Hold |
AlloVir's last stock rating was published by Raymond James on Dec 26, 2023. The company gave ALVR a "Strong Buy" rating, the same as its previous rate.
AlloVir Financial Forecast
AlloVir Revenue Forecast
| Dec 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|
| Revenue | - | - | - | - |
| Avg Forecast | - | - | - | - |
| High Forecast | - | - | - | - |
| Low Forecast | - | - | - | - |
| # Analysts | - | - | - | - |
| Surprise % | - | - | - | - |
AlloVir's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. ALVR's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
AlloVir EBITDA Forecast
| Dec 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|
| # Analysts | - | - | - | - |
| EBITDA | - | - | - | - |
| Avg Forecast | - | - | - | - |
| High Forecast | - | - | - | - |
| Low Forecast | - | - | - | - |
| Surprise % | - | - | - | - |
undefined analysts predict ALVR's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than AlloVir's previous annual EBITDA (undefined) of $NaN.
AlloVir Net Income Forecast
| Dec 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|
| # Analysts | - | - | - | - |
| Net Income | - | - | - | - |
| Avg Forecast | $-21.93M | $-13.85M | $-10.96M | $-11.87M |
| High Forecast | $-21.93M | $-13.85M | $-10.96M | $-11.87M |
| Low Forecast | $-21.93M | $-13.85M | $-10.96M | $-11.87M |
| Surprise % | - | - | - | - |
AlloVir's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ALVR's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
AlloVir SG&A Forecast
| Dec 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|
| # Analysts | - | - | - | - |
| SG&A | - | - | - | - |
| Avg Forecast | - | - | - | - |
| High Forecast | - | - | - | - |
| Low Forecast | - | - | - | - |
| Surprise % | - | - | - | - |
AlloVir's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to ALVR last annual SG&A of $NaN (undefined).
AlloVir EPS Forecast
| Dec 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|
| # Analysts | - | - | - | - |
| EPS | - | - | - | - |
| Avg Forecast | $-0.19 | $-0.12 | $-0.10 | $-0.10 |
| High Forecast | $-0.19 | $-0.12 | $-0.10 | $-0.10 |
| Low Forecast | $-0.19 | $-0.12 | $-0.10 | $-0.10 |
| Surprise % | - | - | - | - |
According to undefined Wall Street analysts, AlloVir's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ALVR previous annual EPS of $NaN (undefined).
AlloVir Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ALVR | AlloVir | $0.46 | $34.00 | 7291.30% | Buy |
| BDTX | Black Diamond Therapeutics | $2.50 | $20.00 | 700.00% | Buy |
| FDMT | 4D Molecular Therapeutics | $6.32 | $38.33 | 506.49% | Buy |
| AVTE | Aerovate Therapeutics | $2.56 | $13.00 | 407.81% | Hold |
| ANEB | Anebulo Pharmaceuticals | $1.31 | $6.00 | 358.02% | Buy |
| ANTX | AN2 Therapeutics | $1.34 | $5.00 | 273.13% | Buy |
| ACRV | Acrivon Therapeutics | $7.21 | $22.50 | 212.07% | Buy |
| ANAB | AnaptysBio | $15.99 | $49.83 | 211.63% | Buy |
| CGEM | Cullinan Oncology | $11.49 | $34.00 | 195.91% | Buy |
| MLYS | Mineralys Therapeutics | $12.35 | $30.00 | 142.91% | Buy |
| ADAG | Adagene | $2.10 | $5.00 | 138.10% | Buy |
| STOK | Stoke Therapeutics | $12.10 | $26.50 | 119.01% | Buy |
| MRUS | Merus | $44.90 | $81.25 | 80.96% | Buy |
| LYEL | Lyell Immunopharma | $0.65 | $1.00 | 53.85% | Hold |
| AGIO | Agios Pharmaceuticals | $41.96 | $53.50 | 27.50% | Buy |
| CRNX | Crinetics Pharmaceuticals | $55.37 | $69.00 | 24.62% | Buy |
| KRON | Kronos Bio | $0.96 | $1.00 | 4.17% | Buy |